BioSpace News Archive

High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the key secondary endpoint

Case Study Published in JAMDA and Presented at AMDA Highlights How Early Warning Indications Allow Staff to Identify Acute Changes of Condition For Preventative Action [20-May-2020] WOBURN, Massachusetts , May 20, 2020 / PRNewswire/ -- EarlySense , the global leader in contact-free, continuous monitoring solutions for the healthcare continuum, announced tha

Parexel’s leading Real-World Evidence expertise combined with Microsoft’s innovative cloud technology will support physicians and researchers in better understanding and adjusting treatment in real-time

OpSens Inc. reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, a pressure guidewire for the diagnosis and treatment of coronary artery stenosis.

The Korean biotech company Macrogen (CEO Sukang Lee) (KOSDAQ: 038290), announced that it obtained export approval for COVID-19 test kit ‘Axen TM COVID-19 RT’ from the Ministry of Food and Drug Safety (MFDS) on the 18 th.

25-year Healthcare Veteran Takes the Reins as Company Sales Projected to Expand during the Current Fiscal Year G. Darcy Klug to Remain as Chairman and CFO [20-May-2020] LAFAYETTE, Louisiana , May 20, 2020 /PRNewswire/ -- RedHawk Holdings Corp. (OTC: SNDD) (“RedHawk” or the “Company”), a diversified holding company primarily engaged in the sales and distrib

- Data supports pharmacokinetic and safety profile for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults - Data also further highlights the permeation enhancer potency of Intravail® for both small and large molecules; Intravail is a key component of VALTOCO formulation [20-May-2020]

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO s

As part of its ongoing work to advance potentially transformational medicines, GlaxoSmithKline plc will present new data at the upcoming 2020 American Society of Clinical Oncology (ASCO) Annual Meeting from 29-31 May 2020 .

Precision NanoSystems to Prese CanSinoBIO will license in Precision NanoSystems’ proprietary RNA vaccine platform technology Precision NanoSystems will lead RNA vaccine formulation development CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials TIANJIN, China and VANCOUVER , May 20, 2020 /PRNewswire/ - CanSino Biologics Inc. (Ca